PRESS RELEASE NORTH CHICAGO, Ill.andSUNNYVALE, Calif.,March 4, 2015/PRNewswire/ –AbbVie and Pharmacyclics today announced a definitive agreement under which AbbVie will acquire Pharmacyclics, and its flagship asset Imbruvica® , a effective treatment for hematologic malignancies highly canada pharmacy . The acquisition accelerates AbbVie's clinical and business presence in oncology, strengthening its currently robust pipeline, and establishing its strong leadership position in hematological oncology – an attractive and rapidly growing market, right now approaching$24billionglobally. The acquisition adds to AbbVie's already in depth pipeline and strong growth prospects.
While genotype 1 is the most prevalent type of HCV in the U.S., accounting for about 73 % of most cases, GT4 infection accounts for up to 6 % of HCV infections. Hepatitis C is irritation of the liver caused by contamination with HCV. It really is transmitted when an contaminated person's bloodstream enters the bloodstream of another person. There are six main HCV genotypes . Presently, there is no vaccine for HCV infection.. AbbVie’s all-oral, interferon-free of charge therapy granted FDA priority review for treatment of GT4 HCV infection AbbVie has announced that the U.S. Food and Drug Administration has recognized its New Drug Software and granted priority review for the firm's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir , with ribavirin .